Platform or Pipeline? Separating the Value in AI Drug-Discovery M&A

A Valuation and Transaction Framework for Repeatable Discovery Capability, Therapeutic Assets, Partnerships, Data and Post-Combination Value Creation

Authored by Chennakeshav Adya

Independent Researcher

September 2026

Abstract

Artificial intelligence drug-discovery companies often present themselves as integrated engines in which proprietary data, computational models, automated laboratories, scientists, therapeutic programmes and pharmaceutical partnerships reinforce one another. This structure can create real strategic value. It can also obscure where enterprise value resides. A buyer can pay for a repeatable platform, individual drug candidates, contingent partnership economics and buyer-specific synergy while relying on the same scientific evidence more than once.

This paper develops a transaction framework for separating those value components in mergers and acquisitions. It defines a platform as a governed capability that can repeatedly convert defined biological questions into experimentally validated development candidates with measurable improvements in quality, time, cost or probability. It defines pipeline value at the asset level, using rights, indication, development stage, evidence, remaining investment, timing and risk. Partnership value is reconstructed from executed contracts, funded research, option rights, milestones, royalties, cost sharing and collected cash. Data, models, laboratory systems, people and intellectual property are tested as productive assets within that architecture rather than treated as an undifferentiated artificial-intelligence premium.

The analysis draws on current material from the US Food and Drug Administration, European Medicines Agency, International Council for Harmonisation, US Securities and Exchange Commission filings, public transaction documents, competition authorities, accounting and valuation standard setters, patent authorities and peer-reviewed evidence on drug-development productivity.[1][2][3][4][5][6][7][8][9][10] FDA and EMA materials emphasise context of use, risk-based model credibility, data governance, performance assessment and lifecycle management. Public disclosures show materially different business models: software licences, research services, milestones, royalties, internal programmes and combinations of those elements.

A wholly hypothetical acquisition case illustrates a business with software and research revenue, six internal programmes and four strategic collaborations. Every programme probability, duration, revenue, cost, milestone, royalty, multiple and valuation amount is a management assumption created solely to demonstrate the method. None is a forecast, market benchmark, scientific claim or valuation opinion.

The paper concludes that platform value is supportable when the same governed system produces reproducible improvement across independent programmes, retains lawful access to differentiated data, survives key-person and infrastructure transfer, and creates contractual or pipeline economics beyond the assets already valued. Six figures and seven tables translate that conclusion into a value architecture, reproducibility scorecard, programme map, partnership waterfall, valuation bridge, integration design and 180-day programme.

Drug-development, clinical, regulatory, patent, privacy, competition, tax, accounting and corporate-law requirements vary by asset and jurisdiction. Qualified scientific, clinical, regulatory, legal, accounting, tax and valuation specialists should determine the rules and evidence applicable to a specific technology and transaction.

JEL Classification: G24, G34, I11, O32, O33

Keywords: artificial intelligence, drug discovery, biotechnology, platform valuation, therapeutic pipeline, mergers and acquisitions, pharmaceutical partnerships, intangible assets

JEL Classification: G24, G34, I11, O32, O33

Keywords: artificial intelligence, drug discovery, biotechnology, platform valuation, therapeutic pipeline, mergers and acquisitions, pharmaceutical partnerships, intangible assets

1. Define the acquisition decision

The transaction question is whether the target owns a repeatable discovery capability, a portfolio of therapeutic assets, a set of contingent contracts, or a combination of the three. Each component has a different evidence base, risk pattern, capital requirement and integration path. The buyer should define them before selecting a valuation method or negotiating consideration.

A platform claim should describe an operating system, not a collection of attractive technologies. The system begins with a defined biological question and governed inputs. It generates hypotheses or molecules, selects experiments, receives wet-lab or clinical feedback, updates models under change control and produces a decision that advances, redesigns or stops a programme. Repeatability requires comparable evidence across programmes and over time.

Pipeline assets are specific therapeutic rights. Their value depends on target, modality, indication, differentiation, preclinical and clinical evidence, intellectual property, regulatory pathway, competitive landscape, remaining cost, development control and commercial rights. A promising candidate can be valuable without proving that the underlying discovery platform is repeatable.

Partnerships create a third value perimeter. Upfront fees, research funding, option payments, development milestones, sales milestones, royalties, co-development rights and cost obligations should be separated. A large disclosed headline may represent contingent payments across numerous programmes and decades. It should not be treated as contracted revenue or enterprise value.

The acquisition thesis should state which value is current, protected, funded, contingent and buyer-specific. It should also show where the platform and pipeline interact. Platform evidence can affect the probability, cost and timing assigned to pipeline assets. The pipeline must not then receive the same platform improvement a second time.

2. Build a platform–pipeline–partnership architecture

The buyer should create three linked ledgers. The platform ledger records data rights, model families, scientific workflows, laboratory systems, software, quality controls, personnel, productivity evidence and external adoption. The pipeline ledger records each programme, rights, indication, stage, evidence, cost, timing, probability and value. The partnership ledger records executed contractual economics and responsibilities.

This architecture prevents narrative transfer. A presentation may cite a clinical-stage candidate as proof of platform quality, include that candidate's risk-adjusted value in the pipeline, and capitalise the same proof into a platform multiple. The ledgers force the team to identify the precise evidence and its permitted valuation use.

The architecture should also distinguish internal, partnered and sold assets. A target may retain all economics in one programme, a royalty in another, an option right in a third and no rights after a discovery handoff in a fourth. Programme count is therefore a weak value measure.

Figure 1. Proposed AI drug-discovery value architecture



The three ledgers interact, but each economic benefit should have one primary valuation location.

Table 1. Value-component ledger

Component	Evidence unit	Primary method	Main double-counting risk
platform	independent programme and workflow	incremental cash flow, relief-from-royalty or replacement economics	pipeline success counted as platform proof and asset value
internal pipeline	asset, indication and jurisdiction	risk-adjusted net present value	platform benefit embedded twice in probability or cost
partnered pipeline	contractual programme	expected contractual cash flow	total headline milestones treated as earned value
software and services	customer cohort and contract	income approach and supported market evidence	research revenue treated as recurring software
data and models	governed right and productive use	incremental income or replacement evidence	historical cost treated as economic value
buyer synergy	named initiative and owner	buyer-specific discounted cash flow	included in seller stand-alone value and acquisition premium

Proposed transaction architecture; rights and economics require contract-level verification.

3. Define a repeatable discovery platform

A repeatable platform produces evidence across independent programmes, not merely repeated use of the same software. The buyer should identify the context of use for each model: target identification, structure prediction, molecule generation, property prediction, toxicity, patient stratification, trial design or another decision. FDA's risk-based framework for AI supporting drug-development decisions connects credibility to the specific context of use.[1] EMA similarly emphasises intended use, data governance, model performance and lifecycle control.[2]

Repeatability requires a stable measurement system. For each programme, the target should record starting hypothesis, input data, model and version, candidate set, selection rule, experiments, failures, design cycles, elapsed time, cost and progression decision. Retrospective claims assembled after success provide weaker evidence than contemporaneous governed records.

The comparator matters. A platform should be compared with a credible alternative for the same problem. An easy target, inherited lead series or unusually rich dataset can make a workflow appear productive. Comparisons should control for modality, target difficulty, endpoint, stage and work transferred to partners.

The strongest evidence spans multiple teams, targets, modalities and time periods. It also includes terminated programmes. Failure data reveal whether the system recognises uncertainty and stops weak work. A platform that generates more candidates without improving selection can shift cost downstream.

4. Reconstruct the design–make–test–learn loop

The operating loop should be traced from decision to evidence. Design can involve target hypotheses, molecular structures, sequences, properties or experiments. Make includes synthesis, expression, assay preparation and data engineering. Test covers computational and physical experiments. Learn means that governed results change models, selection rules or scientific decisions.

The buyer should measure cycle time at each transition. A model may generate structures in minutes while synthesis, assay capacity, data curation or scientific review takes months. The relevant throughput is validated decisions per unit of elapsed time and capital. Compute speed alone does not establish enterprise productivity.

Wet-lab integration is a potential differentiator and a cost centre. Automated experiments can create proprietary data and shorten iteration. Their value depends on assay relevance, reproducibility, capacity utilisation, maintenance, sample quality and the ability to transfer operations. A laboratory optimised for one modality may not support the buyer's target portfolio.

Learning should be demonstrated. The team should test whether prediction error, hit rate, selectivity, developability, cycle time or decision quality improves as governed data accumulate. Model releases and experiment lineage should permit reconstruction. If every programme uses bespoke methods and scientists, the business may be a high-quality research organisation rather than a scalable platform.

Figure 2. Proposed evidence map for the design–make–test–learn loop



Productive learning requires traceable decisions, experiments and model change across complete cycles.

5. Test platform reproducibility

Reproducibility has technical, experimental and organisational layers. Technical reproducibility asks whether the same inputs, code, model artefacts and environment produce the same outputs within defined tolerance. Experimental reproducibility asks whether physical results can be repeated under controlled methods. Organisational reproducibility asks whether another qualified team can operate the system and reach a supported decision.

The diligence team should reproduce a sample of material analyses from raw governed input to output. It should select successful, failed and active programmes. Reproduction should use documented infrastructure and ordinary personnel rather than a founder-led demonstration. Differences should be classified and resolved.

Prospective holdouts provide stronger evidence of predictive value than reconstructed historical benchmarks. Public datasets can support comparison, but leakage and benchmark familiarity must be assessed. Proprietary data can improve relevance if lawful, sufficiently large, well annotated and representative. Proprietary status alone does not establish quality.

Scientific audit should challenge the decision threshold. A model can improve one metric while failing the multi-parameter profile required for a drug candidate. The team should examine potency, selectivity, pharmacokinetics, safety, manufacturability and indication-specific requirements together.

Benchmark construction requires particular care. Training and test compounds can share scaffolds, targets, assays or laboratory history in ways that inflate apparent generalisation. The diligence team should examine temporal splits, scaffold splits, prospective experiments and external replication. It should retain denominator data showing every generated, synthesised, tested and advanced candidate. A success rate calculated only from selected molecules cannot establish platform productivity.

Uncertainty should influence action. Calibrated confidence, applicability-domain controls and abstention can be more valuable than universal predictions. The buyer should identify how uncertainty changes experiment selection, programme escalation and human review. A platform that states limits and routes unsupported questions can preserve capital more effectively than one that produces confident output for every target.

Table 2. Platform reproducibility scorecard

Layer	Test	Strong evidence	Failure signal
data	reconstruct lineage and rights	governed source, transformations and permissions	undocumented or non-transferable corpus
model	rerun versioned artefacts	reproducible output and calibrated uncertainty	unavailable code, weights or environment
experiment	repeat material assays	prespecified repeat within tolerance	selective or irreproducible wet-lab result
decision	reconstruct candidate selection	contemporaneous criteria and alternatives	success narrative assembled after outcome
programme	compare independent projects	improvement across varied targets	one flagship carries the evidence claim
organisation	transfer workflow to another team	documented operation without key-person rescue	tacit founder or scientist dependency

Proposed scorecard; scientific specialists should set programme-specific tests and tolerances.

Figure 3. Hypothetical cross-programme platform-evidence matrix



Illustrative management scores from one to five; scores are not scientific benchmarks or target assessments.

6. Diligence data as an economic asset

Data value depends on rights, relevance, quality, uniqueness, refresh and productive use. The buyer should identify whether data are owned, licensed, publicly sourced, generated for partners, derived from patient material or restricted by consent and contract. Rights to use data for one collaboration may not permit model training, commercial reuse or transfer on change of control.

Provenance should connect every material record to source, collection method, consent or licence, transformations, quality checks and deletion obligations. Biological and chemical data need units, assay conditions, controls, batch information and negative results. A large corpus with heterogeneous experimental conditions can create false confidence.

The data moat should be tested through ablation or comparative experiments where feasible. The question is how much performance or decision quality changes when the differentiated dataset is removed, aged or applied to another programme. Value should reflect productive contribution, not storage volume.

Data refresh can create recurring cost and strategic dependence. External databases, clinical partners, contract laboratories and cloud providers may be essential. The buyer should model renewals, price changes, service continuity, export rights and technical migration. Derived models may remain contractually contaminated even when raw data are deleted.

7. Diligence models, software and compute

The model inventory should include foundation models, task-specific models, physics-based methods, rules, ranking systems and human decision points. Each item needs purpose, owner, training data, version, performance, uncertainty, deployment use, dependencies and retirement criteria. Marketing labels should not replace technical boundaries.

Source code, weights, feature pipelines, simulation tools and third-party components should be mapped to ownership and licence. Open-source obligations, research licences and cloud marketplace terms can constrain commercial deployment. The buyer should test whether a critical model can run in the expected environment and whether required data can lawfully travel with it.

Compute economics belong in the platform model. Training, simulation, inference, storage and data movement can be material. Falling unit compute cost can expand use while weakening scarcity claims. The target should show productivity per dollar and per decision rather than raw processor count.

Cybersecurity and research integrity are value controls. Model theft, data poisoning, access leakage and unreproducible notebooks can damage pipeline and partnerships. Identity, environment segregation, logging, backup, incident response and validated release processes should cover research as well as production systems.

Vendor concentration should be modelled explicitly. A research workflow may rely on one cloud provider, accelerator architecture, foundation model, chemistry package or electronic laboratory notebook. The buyer should identify portability, egress cost, licence continuity, service-level commitments and export restrictions. A technically transferable model can remain economically captive when retraining data, specialised kernels or workflow orchestration cannot move on reasonable terms.

Technical debt should be separated from scientific uncertainty. Unsupported libraries, inconsistent environments and undocumented pipelines can be remediated through engineering. Weak labels, confounded experiments or absent negative results can require new science. Their cost, timing and effect on platform claims differ and should be shown separately in the integration plan.

8. Diligence intellectual property and freedom to operate

Patent diligence should separate platform methods, data-generation systems, compositions of matter, uses, formulations and manufacturing. Composition and use claims tied to a therapeutic candidate often have different enforceability and duration from computational-method claims. Trade secrets can protect data, parameters and laboratory know-how if controls preserve secrecy.

Inventorship and ownership require programme-level review. Employees, founders, universities, hospitals, consultants, contract research organisations and partners may have contributed. Assignment gaps or background intellectual property can restrict use. AI-assisted invention raises additional policy and evidentiary questions, while current patent systems generally require human inventors.[29][30]

Freedom to operate should cover the intended product and development plan. A platform patent does not establish freedom to develop a candidate. Conversely, a candidate's patent estate does not prove that the buyer can continue using the target's computational and laboratory systems.

The transaction should identify prosecution, maintenance, opposition, litigation, publication and confidentiality deadlines. Integration can change who accesses trade secrets and which licences apply. Clean-team and access controls may be needed before closing.

9. Value pipeline assets one by one

Each therapeutic programme should have an asset sheet covering target, modality, indication, product profile, stage, evidence, intellectual property, rights, competition, regulatory path, remaining development, manufacturing and commercial assumptions. Related indications can be modelled separately where evidence and economics differ.

Risk-adjusted net present value should use explicit probabilities for the relevant stage transitions. Published development probabilities can inform challenge but should not replace asset-specific assessment.[35][36] The buyer should test whether the target's platform changes a particular transition probability and whether evidence supports the magnitude.

Remaining cost includes discovery, preclinical, clinical, regulatory, chemistry, manufacturing, controls and post-approval commitments. Timeline should reflect enrolment, endpoints, regulators, manufacturing and financing. A faster discovery process may have limited effect when clinical development dominates time and capital.

Competitive value should focus on the target product profile. First-in-class and best-in-class claims require evidence against current and expected standards. Crowded targets, biomarker constraints, safety, delivery and combination strategies can alter value materially.

Portfolio correlation should remain visible. Several candidates can depend on the same target hypothesis, modality, assay, delivery technology or biomarker. Counting them as independent options can overstate diversification. The buyer should map common scientific and operational failure modes and run portfolio scenarios that remove an entire mechanism, platform component or partner.

Manufacturing readiness can become the controlling asset risk. A computationally attractive molecule or biologic still needs a robust process, analytical methods, specifications, stability and scalable supply. The development plan should identify when chemistry, manufacturing and controls work enters the critical path and whether the target owns the relevant know-how or relies on a constrained supplier.

Table 3. Programme-level pipeline valuation sheet

Dimension	Required evidence	Valuation use	Control against double counting
rights	ownership, territory, indication and encumbrance	addressable economics	exclude rights already granted to partner
development stage	governed package and regulator interaction	transition probability	use actual stage, not platform narrative
differentiation	product profile and comparative evidence	price, share and duration	separate candidate quality from model quality
remaining cost	study, manufacturing and regulatory plan	cash flow and financing	include platform operating cost once
timing	critical path and dependencies	discount period and option expiry	distinguish discovery speed from clinical time

Dimension	Required evidence	Valuation use	Control against double counting
competition	approved and developing alternatives	probability and terminal value	refresh at valuation date

Proposed structure; all scientific, probability, cost and commercial inputs require asset-specific support.

10. Separate platform proof from pipeline value

A pipeline event can support both a candidate and the platform, but the uses should be explicit. A candidate reaching nomination can show that a workflow completed one discovery cycle. It does not prove clinical success or repeatability. A successful clinical readout primarily affects that asset unless the causal contribution of the platform to a generalisable development decision is demonstrated.

The buyer should maintain an evidence-allocation table. Each event receives one primary valuation effect and any secondary platform effect is bounded. For example, a validated structure prediction may strengthen a model capability while the molecule's commercial value remains in the asset. A partnership option exercise can support external validation and create contractual cash flow; the full future milestone pool remains contingent.

Platform value can be estimated from incremental programme economics after pipeline value is calculated without that increment. If supported evidence indicates fewer design cycles, lower synthesis cost or higher candidate-quality probability, the benefit should enter either the programme assumptions or a separate platform cash flow, not both.

Where evidence remains sparse, the platform can be treated as an option or enabling asset with staged consideration. This preserves upside without converting unverified repeatability into closing value.

11. Reconstruct partnerships and contingent economics

Partnership announcements should be reconciled to signed contracts. The team should identify programmes, targets, exclusivity, research term, funded work, option windows, development control, cost sharing, milestones, royalties, termination, rights reversion, data ownership and change-of-control provisions.

Headline potential milestones are not contracted revenue. They may require every programme to achieve every event, include sales thresholds far in the future and exclude the cost of work. Expected value should use programme-specific probabilities, timing, tax, cost and partner behaviour. Option rights can allow a partner to select only the strongest assets.

Research funding should be distinguished from margin. It may reimburse scientists, experiments and infrastructure with limited contribution. Upfront payments can compensate for licences, exclusivity, research and past work. Revenue recognition does not by itself identify economic value or cash durability.

Partner concentration matters. A platform with several announced collaborations may depend on one pharmaceutical group or a narrow set of decision makers. The buyer should review option exercises, extensions, terminations, programme transfers, cash collection and the proportion of internal capacity reserved for each partner.

Figure 4. Proposed partnership-economics waterfall



Wholly hypothetical USD millions; contingent pools are probability- and time-weighted and are not forecasts.

Table 4. Partnership contract reconstruction

Economic item	Evidence	Valuation treatment	Common error
upfront payment	contract, invoice and cash	recognise earned rights and obligations	treating all cash as recurring revenue
research funding	work plan, cost and margin	forecast funded contribution	ignoring capacity and delivery cost
option payment	option terms and decision gate	probability-weight by programme	assuming every option is exercised
development milestone	event definition and responsibility	probability- and time-weight	applying one portfolio probability
sales milestone	thresholds and product economics	model after approval and launch	including full disclosed pool at close
royalty	base, rate, deductions and term	risk-adjusted product cash flow	applying royalty to unowned geography
co-development right	cost share and governance	model both investment and economics	valuing profit share without funding duty

Proposed contract map; accounting, legal and scientific review should be reconciled.

12. Rebuild software and research-service economics

Some discovery companies have a commercial software business; others provide research services or platform access. The buyer should separate licence, hosted software, professional services, funded research, milestones and drug-development revenue. Their gross margins, renewal patterns and capital needs differ.

Schrödinger's public reporting separates software and drug-discovery segments, illustrating why a consolidated revenue multiple can obscure economics.[12][13] The buyer should reconcile annual contract value, recognised revenue, invoicing and cash by product and cohort. Hosted transitions can shift recognition timing without changing contract economics.

Customer concentration, renewal, seat expansion, usage, cloud cost, support and scientific services should be measured. A software product used across customer programmes can support repeatability and market validation. Bespoke projects delivered by scientists may scale differently.

Internal pipeline use should not create external revenue. The model should allocate platform operating cost between commercial customers, partnered programmes and internal assets using a documented driver. This allows programme economics and software margin to be compared without hiding cost in central research.

13. Design the platform valuation test

Platform value should be supported through one or more observable economic channels. External software or service cash flow can be valued directly. Internal productivity can be valued through supported reductions in time, cost or attrition across a defined programme portfolio. Partnership origination can create contractual economics. Replacement cost can inform negotiation where it reflects lawful data, infrastructure, people, time and failure risk.

Relief-from-royalty requires a credible royalty base and rate. It may be appropriate for a licensable technology, but a platform used only internally has no automatic royalty market. Historical research expenditure is not value; it is evidence of investment. Recreating the same code without data, workflows, team and learning history may be impossible, while expensive work can still lack commercial utility.

Incremental income should be tied to measured performance. If a platform reduces a defined discovery cycle by six months, the model should identify affected programmes, required operating cost, probability of transfer and economic consequence. Benefits should end when technology becomes standard or the advantage erodes.

Platform terminal value requires durable rights, talent, data generation, customer or partner adoption and model maintenance. Rapid technical change can shorten useful life even where software remains operational. The buyer should avoid applying a perpetual software multiple to a research capability whose advantage depends on continuous scientific investment.

Valuation date discipline is essential. Clinical, patent, competitive, regulatory and partnership information can change quickly. The model should distinguish information known at signing from subsequent events and specify the update process before closing. A later programme failure should not be hidden inside a general platform discount; the affected asset and any genuine read-through to repeatability should be reassessed separately.

Accounting recognition and transaction pricing answer different questions. Purchase-price allocation may identify technology, contracts, in-process research and development, customer relationships or goodwill after the commercial bargain is struck. Those categories can inform useful-life and impairment analysis, yet they do not establish the amount a buyer should pay or remove the need to test overlap among value components.

14. Build the combined valuation

The combined model should begin with stand-alone software and service cash flow. It should add pipeline risk-adjusted value asset by asset, partnership cash flows by contract and platform incremental economics not already embedded. Non-operating assets, debt, preference rights and transaction obligations complete the bridge to equity proceeds.

The wholly hypothetical case contains USD 22 million of software and research revenue, of which USD 9 million is recurring licence revenue. It has six internal programmes, two of which are development candidates, and four collaborations. After attributable delivery, compute, laboratory and support cost, the commercial activity contributes USD 5 million before central research, tax and capital.

The central case assigns USD 42 million to supported commercial cash flow, USD 74 million to internal pipeline assets, USD 28 million to expected partnership economics and USD 24 million to platform productivity that is not embedded in those components. Net cash adds USD 31 million. Integration cost and duplicated infrastructure reduce value by USD 16 million. Illustrative equity value is USD 183 million.

Every amount is hypothetical. The example is designed to expose assumptions and double counting. It is not a market benchmark, forecast or valuation opinion.

Figure 5. Hypothetical platform–pipeline acquisition-value bridge



Wholly hypothetical USD millions; each benefit has one primary valuation location.

15. Test sensitivity without hiding correlation

Platform and pipeline risks are correlated. Weak data provenance can affect several programmes. Loss of a scientific team can slow internal assets and partner work. A model failure can damage future origination. Sensitivity should therefore include shared downside cases rather than varying every programme independently.

Key platform variables include reproducibility, transfer rate, programme throughput, operating cost and useful life. Pipeline variables include transition probability, timing, development cost, product differentiation and market duration. Partnership variables include option exercise, milestone timing, partner termination and cost to deliver.

The hypothetical sensitivity varies internal-pipeline value and supported platform increment. It holds commercial cash flow, partnership economics, net cash and integration cost constant. The cells are arithmetic scenarios and carry no market implication.

Table 5. Hypothetical equity-value sensitivity

Internal pipeline value; USDm	Platform USD 10m	USD 20m	USD 30m	USD 40m
45	140	150	160	170
60	155	165	175	185
75	170	180	190	200
90	185	195	205	215

Downside cases should also show liquidity and financing. A delayed programme can require a new round before an asset event. Preference rights and anti-dilution can affect seller proceeds. The acquisition model should disclose which party funds each development plan.

16. Choose consideration that follows evidence

Closing consideration should reflect value supported at signing. Contingent consideration can address pipeline events, partner options, platform transfer or commercial retention. Each milestone needs a defined asset, evidence package, decision authority, observation period and dispute process.

A regulatory filing is an activity; acceptance, clearance or approval is a stronger event. Candidate nomination can be defined by a product profile and reproducible package. Platform milestones can require independent programme reproduction, validated cycle improvement or partner renewal. Revenue milestones should use collected cash and agreed cost allocation where margin matters.

Contingent value should not reward unsafe acceleration or underinvestment. Operating covenants should preserve appropriate scientific, clinical, quality and regulatory decisions. Seller protections can define minimum resources and consultation while retaining buyer authority to stop a programme for documented reasons.

Equity consideration can align long-term value but transfers market and integration risk. Escrow can address title, rights, data provenance or known contractual exposure. A licence, option or staged acquisition can be appropriate when platform repeatability remains unproven.

17. Translate diligence into transaction protections

Representations should cover corporate authority, intellectual property, inventorship, data rights, privacy, open source, scientific records, regulatory status, clinical work, partnerships, grants, cybersecurity, export controls and financial metrics. Schedules should identify programme and model versions rather than relying on broad knowledge qualifiers.

Conditions may include assignment of essential rights, partner or licensor consent, delivery of model artefacts, closure of a material provenance gap, reproducibility of a defined analysis and retention of critical personnel. Conditions should focus on matters required for lawful ownership or viable operation.

Interim covenants should control material model releases, publication, patent action, programme termination, new encumbrance, partner amendment, unusual data access and loss of key infrastructure. Ordinary scientific work should continue under an agreed change framework.

Indemnity and insurance should reflect recoverability and duration. Known pipeline risk belongs in price or contingent consideration. Title, deliberate misconduct and specified data or patent exposure may require separate treatment. The committee should map every material gap to one primary response so that the same issue is not deducted, escrowed and excluded from value without explanation.

Table 6. Evidence-to-transaction protection matrix

Evidence gap	Valuation response	Protection	Release evidence
platform proven on one programme	limit platform increment	staged consideration	independent programme reproduction
unclear training-data rights	exclude affected use	condition, escrow and indemnity	verified transferable rights
candidate evidence incomplete	probability-weight asset	programme milestone	governed development package

Evidence gap	Valuation response	Protection	Release evidence
headline milestones highly contingent	expected-value contract cash flow	earn-out tied to collected event	partner payment received
key-person workflow	continuity discount	retention and transfer plan	qualified team operates independently
compute or lab dependency	include migration cost	service covenant and transition support	tested replacement environment
overlapping value claims	allocate benefit once	valuation schedule	reconciled ledgers approved

Proposed matrix; legal drafting and remedies remain transaction-specific.

18. Design integration around scientific continuity

Integration can destroy the evidence base by changing data access, model environment, laboratory methods, scientific teams or programme priorities. Day-one design should preserve critical systems and decision records. Cost synergy should follow validated replacement.

The target architecture should classify capabilities as preserve, connect, migrate or retire. Preserve applies where the platform and quality controls remain productive. Connect uses governed interfaces and shared decision rights. Migrate transfers models, data or experiments after matched testing. Retire follows confirmation that obligations, provenance and scientific records remain accessible.

Data migration should retain identifiers, units, assay conditions, lineage, permissions, deletion state and negative results. Model migration should retain code, weights, dependencies, seeds, hardware assumptions and performance. Laboratory migration should compare protocols, equipment, controls and outputs.

Programme governance should remain asset-specific. A combined portfolio committee can prioritise capital, but it should record whether a stop decision reflects scientific weakness, strategic overlap, financing or capacity. That distinction matters for platform learning and contingent payments.

Partner-facing integration needs a separate workstream. Pharmaceutical partners may have audit, security, key-person, subcontracting, publication and change-of-control rights. The buyer should present a continuity plan, preserve agreed teams and obtain consents before moving data or work. An integration saving that causes programme termination can destroy more value than it releases.

Research records should remain inspection-ready. Electronic notebooks, experiment identifiers, samples, model artefacts, decisions, deviations and approvals should survive migration with an audit trail. The combined organisation should test retrieval for one active, one completed and one terminated programme before declaring the record transfer complete.

19. Retain the scientific operating system

Platform value can depend on scientists who connect biology, chemistry, computation, experiments and development. The buyer should map critical decisions, relationships and tacit knowledge. Job titles and publication counts are insufficient.

Retention should be paired with transfer. The plan should document model design, data decisions, assay history, failed hypotheses, partner commitments, programme rationale and regulatory interactions. Authority, access and signing rights should move under controlled procedures.

Founders may embody external credibility and internal arbitration. The buyer should test whether scientific governance works without their intervention. Independent review, reproducible records and clear decision rights reduce concentration.

Incentives should preserve rigorous stopping as well as progression. Teams rewarded only for candidate nominations can increase low-quality throughput. Balanced measures can include reproducibility, cycle improvement, programme quality, partner delivery, documentation and capital discipline.

20. Allocate synergy with evidence

Buyer-specific synergy can arise from targets, data, laboratories, clinical development, distribution, manufacturing and capital. Each synergy needs a named owner, enabling investment, evidence, timing and risk. Access to a large portfolio does not prove that the target platform can serve it.

Programme acceleration should identify the exact bottleneck removed. A buyer's assay, molecule library or disease expertise can improve a defined step. The model should avoid claiming both faster development and higher probability without separate evidence.

Data combination requires rights and compatibility. Larger data can improve learning, expose heterogeneity or create integration burden. The team should pilot a bounded use case and measure decision improvement before capitalising a broad data-network effect.

Cost synergy should distinguish duplicated corporate cost from productive platform capacity. Removing laboratory, engineering or scientific roles can reduce throughput and partner delivery. The synergy ledger should show the control or process that replaces every removed activity.

21. Govern regulatory and model lifecycle risk

AI used to support regulatory decisions should be governed according to its context of use and risk. FDA's draft guidance proposes a credibility framework, and FDA–EMA principles emphasise human-centric design, clear context, data governance, performance assessment and lifecycle management.[1][3] The buyer should map which models generate evidence used in submissions and how changes are controlled.

Models used only for exploratory research can still affect candidate selection and capital allocation. Governance should be proportionate and should preserve data lineage, versioning, performance, uncertainty, human review and decision records. A research label should not excuse irreproducibility.

Generative outputs require scientific validation. Molecules or hypotheses should be screened for feasibility, novelty, safety and manufacturability. The system should record rejected outputs and reasons. This protects learning and helps distinguish platform productivity from selective presentation.

Post-combination governance should establish owners for every material model, dataset, programme and partner deliverable. Change control should identify validation, regulatory, patent, contractual and valuation consequences. A platform remains valuable through controlled evolution rather than frozen technology.

22. Execute an evidence-gated 180-day programme

Days one to thirty should preserve data, models, laboratory operations, partner delivery, programme decisions, patent deadlines and cybersecurity. Governance, access, change restrictions and critical-person coverage should be established. Cash, contracts and programme rights should reconcile.

Days thirty to seventy should reproduce selected analyses and experiments, complete the platform and pipeline ledgers, validate rights, reconstruct partnership economics and confirm asset-level development plans. The team should identify where valuation relied on shared evidence.

Days seventy to one hundred and twenty should test bounded integration: one data connection, one model environment, one laboratory transfer and one joint programme decision. Defects should be resolved before broad migration. Commercial and research-service cohorts should be reviewed for delivery cost and renewal.

Days one hundred and twenty to one hundred and eighty should season transferred workflows, confirm partner performance, update programme probabilities, validate synergy and release contingent value only when agreed evidence passes. The board should receive a reconciled value bridge and capital plan.

Figure 6. Proposed platform–pipeline 180-day programme



Timing should follow scientific, contractual, regulatory and operational dependencies.

Table 7. Board decision gates

Gate	Evidence	Decision	Failure response
continuity	systems, rights, people and partner delivery stable	preserve operations	restrict changes and activate fallback
reproduction	selected models and experiments repeated	accept evidence base	reduce platform value and remediate
allocation	platform, pipeline and contract ledgers reconciled	approve valuation map	remove duplicated benefit
bounded integration	transferred workflow meets tolerance	expand migration	isolate and redesign
seasoning	programme, partner and commercial results persist	release synergy	extend observation or reprice
value release	contractual milestone evidence complete	pay contingent value	dispute or withhold under agreed terms

Proposed governance sequence; transaction-specific accountability should be documented.

23. Decision and conclusion

AI drug-discovery acquisitions require disciplined separation of capability, assets and contracts. A platform is valuable when it repeatedly converts governed biological questions into better validated decisions across independent programmes. A candidate is valuable when its rights, evidence, differentiation, development plan and economics support risk-adjusted cash flow. A partnership is valuable to the extent that enforceable terms create funded work, option payments, milestones, royalties or strategic rights.

The buyer should reconstruct the design–make–test–learn loop, reproduce selected work, validate data and intellectual-property rights, and measure complete-cycle productivity. It should value every therapeutic programme separately and reconcile every partnership from contract to collected cash. Platform benefits should enter the model once.

Closing value can include supported commercial cash flow, pipeline risk-adjusted value, expected partnership economics and a bounded platform increment. Unproven repeatability, future indications and broad network effects can be preserved through milestones, options or staged ownership.

Integration should protect the scientific operating system before pursuing cost savings. Data, models, laboratory methods, people, decision history and partner obligations require controlled transfer. Programme stops should remain scientifically and contractually traceable.

The decisive question is not whether artificial intelligence contributed to a successful molecule. It is whether the acquired system can lawfully and reproducibly create better decisions across the buyer's future portfolio, after the cost of data, compute, experiments, people, governance and capital. That evidence determines whether the buyer is acquiring a platform, a pipeline, or an expensive narrative connecting the two.

Frequently asked questions

Q: What is the difference between an AI drug-discovery platform and a pipeline? A: A platform is a repeatable, governed capability that supports discovery decisions across programmes. A pipeline is a set of specific therapeutic assets with defined rights, evidence, development plans and economics.

Q: Can one successful drug candidate prove platform value? A: It can provide evidence that one workflow completed a cycle. Repeatable platform value requires comparable evidence across independent programmes, including failed work, and a credible causal link to improved quality, time, cost or probability.

Q: How should disclosed pharmaceutical partnership milestones be valued? A: The buyer should reconstruct contract terms and probability-weight each programme, event, timing, cost and partner decision. The maximum disclosed pool should not be treated as earned revenue or closing value.

Q: How can a buyer avoid double counting platform and pipeline value? A: Maintain separate ledgers, give each evidence event one primary valuation effect, and place any supported productivity benefit either in asset assumptions or in a separate platform cash flow.

Q: Does a large proprietary dataset establish a data moat? A: No. The buyer should verify rights, provenance, quality, relevance, refresh cost and measurable contribution to decisions. Size without productive use does not establish economic value.

Q: Which platform metrics matter most? A: Complete-cycle measures matter: reproducible candidate quality, design cycles, elapsed time, experimental cost, decision quality, failure recognition, programme transfer and attributable cash flow.

Q: When is contingent consideration useful? A: It is useful when closing evidence does not support full value. Milestones can address programme progression, partner payments, independent platform reproduction or retained commercial economics.

Q: What should happen during the first 180 days after acquisition? A: Preserve scientific continuity, reproduce material work, validate rights, reconcile programme and contract value, pilot bounded integration, season results and release value only after agreed evidence passes.

References

[1] US Food and Drug Administration, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological

[2] European Medicines Agency, Reflection paper on the use of artificial intelligence in the medicinal product lifecycle https://www.ema.europa.eu/en/use-artificial-intelligence-ai-medicinal-product-lifecycle-scientific-guideline

[3] US Food and Drug Administration, Guiding Principles of Good AI Practice in Drug Development https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development

[4] European Medicines Agency, EMA and FDA set common principles for AI in medicine development https://www.ema.europa.eu/en/news/ema-fda-set-common-principles-ai-medicine-development-0

[5] US Food and Drug Administration, Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products https://www.fda.gov/media/167973/download

[6] International Council for Harmonisation, E6 Good Clinical Practice https://www.ich.org/page/efficacy-guidelines

[7] International Council for Harmonisation, E8 General Considerations for Clinical Studies https://www.ich.org/page/efficacy-guidelines

[8] International Council for Harmonisation, E9 Statistical Principles for Clinical Trials https://www.ich.org/page/efficacy-guidelines

[9] US Securities and Exchange Commission, Recursion Pharmaceuticals 2024 Form 10-K https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm

[10] US Securities and Exchange Commission, Recursion and Exscientia combination completion exhibit https://www.sec.gov/Archives/edgar/data/1865408/000094787124000937/ss4137056_ex9901.htm

[11] US Securities and Exchange Commission, Recursion and Exscientia transaction presentation https://www.sec.gov/Archives/edgar/data/1601830/000160183024000148/exhibit991-rxrxsept2024.htm

[12] US Securities and Exchange Commission, Schrödinger 2025 Form 10-K https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/sdgr-20251231.htm

[13] Schrödinger, 2025 full-year financial results https://ir.schrodinger.com/press-releases/news-details/2026/Schrdinger-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx

[14] US Securities and Exchange Commission, Absci annual report and integrated drug-creation platform disclosures https://www.sec.gov/Archives/edgar/data/1672688/000167268826000080/a202510-kxasfiled.htm

[15] US Securities and Exchange Commission, Absci public-offering prospectus https://www.sec.gov/Archives/edgar/data/1672688/000119312524049377/d783567d424b5.htm

[16] Isomorphic Labs, strategic research collaboration with Novartis https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-strategic-research-collaboration-with-novartis

[17] Isomorphic Labs, strategic research collaboration with Eli Lilly https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-strategic-research-collaboration-with-eli-lilly

[18] Google DeepMind, AlphaFold https://deepmind.google/science/alphafold/

[19] National Institutes of Health, PubChem https://pubchem.ncbi.nlm.nih.gov/

[20] European Bioinformatics Institute, ChEMBL https://www.ebi.ac.uk/chembl/

[21] RCSB Protein Data Bank https://www.rcsb.org/

[22] US Food and Drug Administration, Drug Development and Review Definitions https://www.fda.gov/drugs/investigational-new-drug-ind-application/drug-development-and-review-definitions

[23] US Food and Drug Administration, Investigational New Drug Application https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application

[24] European Medicines Agency, Scientific advice and protocol assistance https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance

[25] ClinicalTrials.gov, study registry https://clinicaltrials.gov/

[26] World Health Organization, International Clinical Trials Registry Platform https://www.who.int/clinical-trials-registry-platform

[27] World Intellectual Property Organization, Artificial Intelligence and Intellectual Property https://www.wipo.int/about-ip/en/artificial_intelligence/

[28] World Intellectual Property Organization, PATENTSCOPE https://patentscope.wipo.int/

[29] United States Patent and Trademark Office, Inventorship Guidance for AI-Assisted Inventions https://www.uspto.gov/subscription-center/2024/inventorship-guidance-ai-assisted-inventions

[30] European Patent Office, Artificial intelligence and machine learning https://www.epo.org/en/legal/guidelines-epc/2025/g_ii_3_3_1

[31] US Federal Trade Commission and Department of Justice, 2023 Merger Guidelines https://www.ftc.gov/reports/merger-guidelines-2023

[32] European Commission, Guidelines on the assessment of horizontal mergers https://competition-policy.ec.europa.eu/mergers/legislation_en

[33] UK Competition and Markets Authority, Merger Assessment Guidelines https://www.gov.uk/government/publications/merger-assessment-guidelines

[34] US Federal Trade Commission, Premerger Notification Program https://www.ftc.gov/enforcement/premerger-notification-program

[35] Wong, Siah and Lo, Estimation of clinical trial success rates and related parameters, Biostatistics https://academic.oup.com/biostatistics/article/20/2/273/4817524

[36] Biotechnology Innovation Organization, Clinical Development Success Rates and Contributing Factors https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020

[37] US Food and Drug Administration, Project Optimus https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus

[38] US Food and Drug Administration, Model-Informed Drug Development Paired Meeting Program https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program

[39] National Institute of Standards and Technology, AI Risk Management Framework https://www.nist.gov/itl/ai-risk-management-framework

[40] International Organization for Standardization, ISO IEC 42001 artificial-intelligence management systems https://www.iso.org/standard/81230.html

[41] International Organization for Standardization, ISO 27001 information-security management systems https://www.iso.org/standard/27001

[42] IFRS Foundation, IFRS 3 Business Combinations https://www.ifrs.org/issued-standards/list-of-standards/ifrs-3-business-combinations/

[43] IFRS Foundation, IAS 38 Intangible Assets https://www.ifrs.org/issued-standards/list-of-standards/ias-38-intangible-assets/
[44] IFRS Foundation, IFRS 13 Fair Value Measurement https://www.ifrs.org/issued-standards/list-of-standards/ifrs-13-fair-value-measurement/
[45] Financial Accounting Standards Board, Business Combinations Topic 805 https://asc.fasb.org/topic&trid=2126139
[46] International Valuation Standards Council, International Valuation Standards https://ivsc.org/standards/
[47] OECD, Recommendation of the Council on Artificial Intelligence https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0449
[48] OECD, Recommendation on Health Data Governance https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0433
[49] European Union, Artificial Intelligence Act https://eur-lex.europa.eu/eli/reg/2024/1689/oj
[50] European Union, General Data Protection Regulation https://eur-lex.europa.eu/eli/reg/2016/679/oj

About the Author

Chennakeshav (CK) is a corporate finance and investment banking executive with 25+ years of global experience in deal origination, structuring and execution across M&A, growth capital and corporate strategy. He has led value-creation mandates for founders, corporates and funds — bridging the boardroom view to hands-on execution and close.

His career spans Morgan Stanley, HSBC, Lloyds Banking Group, EWEC, ADQ portfolio companies and Emirates Growth Fund, across TMT, real estate, fintech, deeptech, cleantech, infrastructure and energy. He has partnered with C-suite leaders, private equity and venture funds, sovereign wealth funds and family offices to finance complex fund raises and scale-up ventures, and has led M&A due diligence, post-merger integration and business-transformation initiatives to create value.

At Matchpoint Partners he is Managing Partner, leading the firm's corporate finance, M&A and capital-raising practice. He holds an MBA from London Business School, an engineering degree from VTU and a Master of Laws (LLM, in progress) from UCL London.

An active start-up mentor, CK mentors at Techstars, DIFC FinTech Hive, Startup Grind, Founder Institute and IN5, serves as Entrepreneur Mentor in Residence (EMiR) at London Business School, and judges the Entrepreneurship World Cup.

https://www.linkedin.com/in/ckadya/

https://www.matchpoint-partners.com/team/ck-adya.html

This paper is part of a continuing series on the structure of private and alternative markets. The views expressed are the author's own. The paper is for information only, describes market structure in general terms, and does not constitute investment, legal, tax or regulatory advice or a recommendation in respect of any security, vehicle or counterparty.